OBSOLETE: Limbic encephalitis associated with antibodies to cell membrane antigens

Limbic encephalitis associated with antibodies to cell membrane antigens was a diagnostic category previously used in Orphanet (code 163903) to describe a form of autoimmune limbic encephalitis in which patients develop antibodies directed against neuronal cell surface or synaptic proteins. This condition is now considered obsolete as a distinct classification because the individual disorders have been reclassified into more specific entities based on the identified target antigen, such as anti-NMDA receptor encephalitis, anti-LGI1 encephalitis, anti-CASPR2 encephalitis, anti-AMPA receptor encephalitis, and anti-GABA-B receptor encephalitis, among others. Limbic encephalitis in general affects the central nervous system, particularly the limbic structures of the brain including the hippocampus, amygdala, and medial temporal lobes. Key clinical features typically include subacute onset of short-term memory loss, seizures, confusion, psychiatric symptoms (such as personality changes, anxiety, and hallucinations), and sleep disturbances. Some forms may be associated with underlying tumors (paraneoplastic), while others occur without cancer (non-paraneoplastic). Treatment generally involves immunotherapy, including corticosteroids, intravenous immunoglobulins, plasma exchange, and in refractory cases, second-line agents such as rituximab or cyclophosphamide. Tumor removal, when applicable, is also a critical component of management. Because this entry is obsolete, patients and clinicians should refer to the specific antibody-defined subtypes for the most current and accurate clinical information.

Common questions about OBSOLETE: Limbic encephalitis associated with antibodies to cell membrane antigens